



Thorough analytical testing is essential to verify the identity, purity, and stability of mRNA vaccines and therapeutics. Leveraging our extensive experience supporting leading mRNA COVID-19 vaccine manufacturers with raw material, drug substance, and drug product release, Avance Biosciences is prepared to assist you in ensuring the quality of your mRNA therapeutics.

mRNA DS/DP Testing (CGMP)

| Critical Quality Attributes | Assay | Description |
|-----------------------------|--|--|
| Identity | mRNA sequence identity confirmation | Confirm the sequence of mRNA by Sanger Sequencing or NGS or RT-qPCR |
| | Identity of RNA mixture | Confirm the presence of multi-valent mRNA drug substance or product using RT-qPCR or ddPCR |
| Content | RNA concentration | Quantify mRNA using UV Spectroscopy, RT-qPCR, or ddPCR |
| | RNA encapsulation efficiency | Determine mRNA/LNP encapsulation efficiency using fluorescence-based assay |
| | RNA Ratio Determination | Confirm the ratio of the mRNAs in multi-valent mRNA vaccine drug substance or product using RT-qPCR or ddPCR |
| Integrity | RNA Size and Integrity | Determine mRNA intactness using CE or Agarose gel electrophoresis |
| Purity | Product related impurities - dsRNA | Detect various dsRNAs using immunoblotting, native and denaturing gel electrophoresis, or ELISA |
| | Process related impurities-residual DNA template | qPCR-based assay to detect potential DNA contamination |



mRNA DS/DP Testing (CGMP)

| Critical Quality Attributes | Assay | Description |
|-----------------------------|--|---|
| Purity | Process related impurities -residual T7 RNA polymerase content | ELISA-based assay to detect potential DNA contamination |
| Potency | Expression of target protein | Develop and validate a custom cell-based assay to determine potency |
| Safety | Endotoxin | USP <85> |
| | Bioburden | USP <61>, <62> |
| | Sterility | USP <71> |
| Other | Appearance | USP <790> |
| | рН | USP <791> |
| | Osmolality | USP <785> |

Preclinical/Clinical Testing (GLP or non-GLP)

| Tests | Description | |
|--|---|--|
| mRNA/LNP Biodistribution Study | Develop and validate RT-qPCR and/or ddPCR assays and test tissues/blood from various animal models under GLP or non-GLP. | |
| Pharmacokinetics (PK) Study | Develop and validate RT-qPCR and/or ddPCR assays and test human bodily fluids for mRNA expression. | |
| Pharmacodynamics (PD) Study | Develop and validate custom assays to measure biomarker levels or protein activity using flow cytometry, Western blot, ELISA, or MSD. | |
| Anti-Drug Antibody (ADA) Analysis | Develop and validate ADA assays by employing multi-tiered testing approach using ELISA, MSD, or Flow Cytometry. | |
| Cytokine Release and Immune Profiling | Develop and validate custom assays to assess the immune response to the mRNA therapeutic using ELISA, MSD, or Flow Cytometry. | |